A Case of Severe Advanced Diabetic Cardiac Autonomic Neuropathy: Severe Orthostatic Hypotension Complicated With Episodes of Nocturnal Supine Hypertensive Emergency Episodes
Abstract
Diabetic cardiac autonomic neuropathy (CAN) is caused by damage to the autonomic nerve fibers that innervate the heart and blood vessels, leading to abnormalities in heart rate control and vascular dynamics. CAN encompasses symptoms such as exercise intolerance, orthostatic hypotension, cardiac denervation syndrome, and nocturnal hypertension. Neurogenic orthostatic hypotension (nOH), resulting from severe diabetic CAN, can cause symptomatic orthostatic hypotension. The management of orthostatic hypotension primarily focuses on preventing severe symptoms, such as syncope and falls. It is equally important to address nocturnal supine hypertension, as it can exacerbate morning orthostatic hypotension. The management strategies for these conditions often complicate each other, highlighting the intricate and delicate nature of treating severe orthostatic hypotension associated with diabetic CAN. We present the case of a 55-year-old male with symptomatic orthostatic hypotension and coexisting nocturnal supine hypertension caused by severe, advanced diabetic CAN.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.